Aptevo Historical Cash Flow
| APVO Stock | USD 9.20 0.47 5.38% |
Analysis of Aptevo Therapeutics cash flow over time is an excellent tool to project Aptevo Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change In Working Capital of 3.1 M or Other Cashflows From Financing Activities of 2.9 M as it is a great indicator of Aptevo Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Aptevo Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Aptevo Therapeutics is a good buy for the upcoming year.
Aptevo |
About Aptevo Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Aptevo balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Aptevo's non-liquid assets can be easily converted into cash.
Aptevo Therapeutics Cash Flow Chart
Add Fundamental
Free Cash Flow
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.Net Borrowings
The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.Most accounts from Aptevo Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Aptevo Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptevo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.At this time, Aptevo Therapeutics' End Period Cash Flow is very stable compared to the past year. As of the 11th of December 2024, Other Cashflows From Investing Activities is likely to grow to about 31 M, while Free Cash Flow is likely to drop (12.3 M).
Aptevo Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
Aptevo Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Aptevo Therapeutics cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Stock Based Compensation | 1.6M | 1.3M | 1.6M | 1.8M | 2.2M | 2.2M | |
| Free Cash Flow | (42.5M) | (29.4M) | (22.4M) | (21.1M) | (11.7M) | (12.3M) | |
| Change In Working Capital | (2.2M) | (2.4M) | (2.7M) | 2.1M | 2.9M | 3.1M | |
| Other Cashflows From Financing Activities | 58K | 21.2M | 26.5M | 2.7M | 3.0M | 2.9M | |
| Depreciation | 2.2M | 1.4M | 1.1M | 901K | 567K | 538.7K | |
| Other Non Cash Items | 673K | 411K | 6.6M | (33.9M) | 10K | 10.5K | |
| Capital Expenditures | 976K | 153K | 88K | 713K | 29K | 0.0 | |
| Total Cash From Operating Activities | (42.4M) | (29.3M) | (21.7M) | (21.0M) | (11.7M) | (12.3M) | |
| Change To Account Receivables | (1.8M) | (2.4M) | (1.3M) | 1.2M | 2.5M | 2.6M | |
| Net Income | (40.4M) | (17.8M) | (28.5M) | 8.0M | (17.4M) | (18.3M) | |
| Total Cash From Financing Activities | 20.1M | 23.9M | 26.2M | (2.6M) | 6.0M | 5.7M | |
| Sale Purchase Of Stock | (58K) | (11K) | 10.2M | (4K) | (10K) | (9.5K) | |
| Change To Inventory | (4.4M) | (1.1M) | 1.3M | (1.2M) | (1.0M) | (995.2K) | |
| Investments | 73.7M | 4.1M | 28.0M | (713K) | (29K) | 0.0 | |
| Change In Cash | (18.1M) | 22.6M | 3.8M | (23.7M) | (5.7M) | (5.4M) | |
| Total Cashflows From Investing Activities | 4.1M | 28.0M | (713K) | (29K) | (33.4K) | (31.7K) | |
| Change To Operating Activities | 3.0M | 665K | 555K | 1.4M | 1.6M | 1.7M | |
| End Period Cash Flow | 19.9M | 42.5M | 46.3M | 22.6M | 16.9M | 23.3M | |
| Change To Netincome | (2.7M) | (10.6M) | 8.3M | (32.1M) | (28.9M) | (27.4M) | |
| Change To Liabilities | 938K | (702K) | (1.9M) | (394K) | (354.6K) | (372.3K) | |
| Begin Period Cash Flow | 38.1M | 19.9M | 42.5M | 46.3M | 22.6M | 25.0M |
Pair Trading with Aptevo Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aptevo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aptevo Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Aptevo Stock
| 0.53 | IMAB | I Mab | PairCorr |
| 0.44 | GNFT | Genfit | PairCorr |
| 0.43 | FLGC | Flora Growth Corp | PairCorr |
| 0.34 | LLY | Eli Lilly | PairCorr |
| 0.32 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
The ability to find closely correlated positions to Aptevo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aptevo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aptevo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aptevo Therapeutics to buy it.
The correlation of Aptevo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aptevo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aptevo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aptevo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptevo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptevo Therapeutics. If investors know Aptevo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptevo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (415.99) | Quarterly Revenue Growth (1.00) | Return On Assets (0.73) | Return On Equity (2.51) |
The market value of Aptevo Therapeutics is measured differently than its book value, which is the value of Aptevo that is recorded on the company's balance sheet. Investors also form their own opinion of Aptevo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aptevo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptevo Therapeutics' market value can be influenced by many factors that don't directly affect Aptevo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptevo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptevo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptevo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.